Display Settings:

Format

Send to:

Choose Destination
    Patol Fiziol Eksp Ter. 2002 Oct-Dec;(4):27-8.

    [Treatment of dyslipoproteinemia by systemic enzyme therapy in experimental glomerulonephritis].

    [Article in Russian]

    Abstract

    Patients with chronic glomerulonephritis (CG) develop disturbances of lipid blood spectrum leading to additional damage to renal structure. The existent methods of pathogenetic therapy have no effect on lipid imbalance. Recently, many autoimmune diseases have been treated with systemic enzyme therapy (SET). The authors studied SET effect in disturbed lipid metabolism in experimental glomerulonephritis. Experimental animals showed morphological and biochemical changes similar to those in CG of man. SET reduced renal tissue damage and symptoms of dyslipoproteinemia.

    PMID:
    12638428
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk